According to a recent study, addition of triglyceride-lowering drug to statins that help fight cholesterol, provide no extra protection from heart problems such as heart attacks, strokes and death from heart failure in patients with Type 2 diabetes.
The study conducted by the National Institutes of Health, intended to know whether the dual-drug therapy is capable of reducing cardiovascular events in diabetics or not, particularly in patients who are at higher risk of serious heart problems due to risk factors like high blood pressure and being overweight.
All subjects were given a cholesterol-reducing Zocor, which is generically available as simvastatin. One of the groups was also given TriCor which is a Fibrate, to reduce the level of blood fat triglycerides and increase HDL cholesterol. The results showed an 8 percent reduction in the risk from the combination therapy but researchers said that the results were not of great significance.
The Data was presented at the American College of Cardiology scientific meeting in Atlanta. The lead investigator of the study Dr. Henry Ginsberg said, “Although our analysis suggests that certain patients may benefit from combination therapy, this study provides important information that should spare many people with diabetes unneeded therapy with fibrates.”